CJC-1295 w/o DAC
Short-acting GHRH analog for pulsatile GH release — ideal with Ipamorelin.
Key Benefits
short half-life produces physiological GH spikes
combines with Ipamorelin for 10× GH amplification
pulsatile pattern preserves long-term pituitary responsiveness
elevated GH supports lean mass and fat reduction
Active Signaling Pathway
Investigated Pathways
Proposed Mechanism
CJC-1295 w/o DAC binds GHRH receptors on pituitary somatotrophs and triggers cAMP-mediated GH synthesis and release. Its short half-life produces discrete GH pulses rather than continuous elevation, preserving the natural pulsatile GH pattern and avoiding receptor desensitization.
Research Highlights
- Produces GH pulses 2–10× above baseline when combined with Ipamorelin
- Short half-life preserves natural GH pulsatility — reduces risk of receptor downregulation
- Synergistic with GHRPs: GHRH + GHRP combination produces 10× more GH than either alone
- Well-characterized pharmacokinetics from multiple preclinical and clinical studies
Human observational or open-label study data exists. Controlled trial data may be limited. Not a treatment recommendation.
For laboratory research only
All Research Systems →Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →Recommended Stacks
CJC-1295 w/o DAC is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
GH Pulse Amplifier
The gold-standard two-signal GH stack — CJC-1295 + Ipamorelin for maximum physiological GH output.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 5mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
CJC-1295 w/o DAC binds GHRH receptors on pituitary somatotrophs and triggers cAMP-mediated GH synthesis and release. Its short half-life produces discrete GH pulses rather than continuous elevation, preserving the natural pulsatile GH pattern and avoiding receptor desensitization.
Clinical Context
The CJC-1295 w/o DAC + Ipamorelin combination is one of the most studied peptide stacks in GH research. The two-signal mechanism (GHRH + GHRP) closely mimics the physiological GH release pattern.
Research Highlights
- Produces GH pulses 2–10× above baseline when combined with Ipamorelin
- Short half-life preserves natural GH pulsatility — reduces risk of receptor downregulation
- Synergistic with GHRPs: GHRH + GHRP combination produces 10× more GH than either alone
- Well-characterized pharmacokinetics from multiple preclinical and clinical studies
Storage & Reconstitution
Store at -20°C. Reconstitute with 2 mL bacteriostatic water → 2.5 mg/mL. Stable 30 days at 2–8°C.
Key Studies
Long-acting growth hormone releasing factor (CJC-1295) stimulates GH and IGF-1 secretion
Ionescu M et al.
Comparison of CJC-1295 with and without DAC confirmed that the no-DAC version produces discrete GH pulses preserving pulsatile physiology.
PubMed →GH pulsatility and aging
Sackmann-Sala L et al.
Pulsatile GHRH stimulation preserves GH axis responsiveness better than continuous stimulation in aging models.
PubMed →GHRH + GHRP synergy in GH release
Veldhuis JD et al.
GHRH + GHRP combination produces 10× more GH than either peptide alone by activating both signals of the two-signal GH release mechanism.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Pulsatile GH release from pituitary somatotrophs — preserves natural GH pattern
Discrete GH pulses 2–10× above baseline when combined with GHRP
Downstream hepatic IGF-1 production following GH pulse
Side Effects & Adverse Events
- Injection site reactions
- Flushing
- Headache
- Water retention
- Joint discomfort
- None documented
Contraindications & Interactions
Synergistic Compounds
The classic GHRH + GHRP combination — produces 10× more GH than either peptide alone.
CJC-1295 w/o DAC 100–200 mcg + Ipamorelin 200 mcg in same syringe, SubQ pre-sleep.
View Compound →Both are GHRH analogs; can alternate to prevent receptor desensitization while maintaining pulsatile GH protocols.
Alternate CJC-1295 w/o DAC and Sermorelin weekly to prevent receptor downregulation.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States